Earlier research suggests that the co-morbidity of thyroid and breast malignancies may be due to immunologically significant cross-talk, as the expression of estrogen receptor (ER) and thyroid hormone receptor (TR) was observed to increase, potentially contributing to the co-morbidity (45). Here, ESR1 is linked to thyroiditis.